Cubist Systematic Strategies’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-293,675
| Closed | -$893K | – | 3674 |
|
|
2024
Q4 | $893K | Buy |
293,675
+63,066
| +27% | +$275K | 0.01% | 1862 |
|
|
2024
Q3 | $1.2M | Buy |
+230,609
| New | +$1.15M | 0.01% | 1720 |
|
|
2024
Q2 | – | Sell |
-35,521
| Closed | -$175K | – | 4230 |
|
|
2024
Q1 | $175K | Sell |
35,521
-269,926
| -88% | -$1.6M | ﹤0.01% | 3135 |
|
|
2023
Q4 | $2.68M | Buy |
305,447
+85,234
| +39% | +$698K | 0.02% | 1291 |
|
|
2023
Q3 | $2.53M | Sell |
220,213
-40,594
| -16% | -$780K | 0.02% | 1204 |
|
|
2023
Q2 | $6.6M | Buy |
260,807
+87,121
| +50% | +$2.71M | 0.04% | 675 |
|
|
2023
Q1 | $5.59M | Sell |
173,686
-109,141
| -39% | -$3.4M | 0.03% | 838 |
|
|
2022
Q4 | $5.22M | Buy |
282,827
+176,199
| +165% | +$4.03M | 0.03% | 975 |
|
|
2022
Q3 | $2.88M | Sell |
106,628
-138,584
| -57% | -$2.81M | 0.02% | 1633 |
|
|
2022
Q2 | $3.39M | Buy |
245,212
+221,707
| +943% | +$3.41M | 0.02% | 1340 |
|
|
2022
Q1 | $458K | Sell |
23,505
-32,001
| -58% | -$485K | ﹤0.01% | 2590 |
|
|
2021
Q4 | $906K | Buy |
55,506
+35,608
| +179% | +$594K | 0.01% | 1987 |
|
|
2021
Q3 | $554K | Sell |
19,898
-14,800
| -43% | -$422K | 0.01% | 1962 |
|
|
2021
Q2 | $1.03M | Buy |
34,698
+27,008
| +351% | +$779K | 0.01% | 1554 |
|
|
2021
Q1 | $215K | Buy |
+7,690
| New | +$213K | ﹤0.01% | 2423 |
|
|
2020
Q4 | – | Sell |
-34,052
| Closed | -$856K | – | 2744 |
|
|
2020
Q3 | $856K | Buy |
+34,052
| New | +$893K | 0.01% | 1428 |
|
|
2020
Q2 | – | Sell |
-108,435
| Closed | -$1.6M | – | 2554 |
|
|
2020
Q1 | $1.6M | Buy |
108,435
+62,350
| +135% | +$1.29M | 0.04% | 569 |
|
|
2019
Q4 | $748K | Buy |
+46,085
| New | +$715K | 0.01% | 1336 |
|
|
2019
Q3 | – | Sell |
-35,982
| Closed | -$467K | – | 2538 |
|
|
2019
Q2 | $467K | Buy |
35,982
+471
| +1% | +$5.94K | 0.01% | 1521 |
|
|
2019
Q1 | $560K | Buy |
+35,511
| New | +$616K | 0.02% | 1115 |
|
|
2018
Q3 | – | Sell |
-8,795
| Closed | -$241K | – | 2124 |
|
|
2018
Q2 | $241K | Buy |
8,795
+2,654
| +43% | +$79.8K | 0.01% | 1224 |
|
|
2018
Q1 | $189K | Buy |
+6,141
| New | +$198K | 0.01% | 1427 |
|
Other funds holding RVNC
Cubist Systematic Strategies's RVNC Position: Q1 2025 in Review
Cubist Systematic Strategies sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 293,675 shares — an estimated $893K sold.
Cubist Systematic Strategies first reported a position in RVNC in Q1 2018 and held it in 22 quarters. The position peaked at $6.6M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Cubist Systematic Strategies reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Cubist Systematic Strategies sold 293,675 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $893K.
- Cubist Systematic Strategies first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 22 quarters.
- Cubist Systematic Strategies's Revance Therapeutics, Inc. position peaked at $6.6M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.